Stockscreener 앱 받기
8.29
1.22%
0.10
시간 외 거래:
8.12
-0.17
-2.05%
Atrium Therapeutics Inc 주식(RNA)의 최신 뉴스
Form 4 Atrium Therapeutics Inc For: 27 September By Investing.com - Investing.com Canada
Atrium Therapeutics stock advances its RNA pipeline toward Phase I/ II - AD HOC NEWS
RNA: Atrium Therapeutics Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Atrium Therapeutics CMO Steven George Hughes Reports Tax-Related Share Withholding on RSU Vesting - Kalkine Media
Form 4 Atrium Therapeutics Inc For: 22 September - Investing.com India
Form 4 Atrium Therapeutics Inc For: 22 September By Investing.com - Investing.com Australia
Atrium Therapeutics (RNA) CSO now holds 41K shares after RSU tax withholding - Stock Titan
21K Atrium Therapeutics (RNA) shares withheld for CMO's taxes - Stock Titan
Director at Atrium Therapeutics (RNA) has 22,812 shares withheld for taxes - Stock Titan
Tax withholding trims Atrium Therapeutics (RNA) director's stake - Stock Titan
2,375 Atrium Therapeutics (RNA) shares withheld for taxes - Stock Titan
Tax withholding trims 11,632 Atrium Therapeutics (RNA) shares, not a market sale - Stock Titan
Atrium Therapeutics (RNA) executive now holds 38,340 shares after tax move - Stock Titan
One new hire gets 13,500 options and 6,750 stock units from Atrium Therapeutics - Stock Titan
Atrium Therapeutics, Inc.Common Stock (Nasdaq:RNA) Price Chart - The Chronicle-Journal
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Riding the Wave of a 141% Potential Upside - DirectorsTalk Interviews
Atrium Therapeutics at Wells Fargo conference: heart-rna push gains pace - Investing.com Nigeria
Atrium Therapeutics, Inc. (RNA): Analyst Consensus Highlights 76% Potential Upside for Biotechnology Innovator - DirectorsTalk Interviews
Atrium Therapeutics, Inc. (RNA) Stock Price, News, Quote & History - Yahoo Finance
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real - Yahoo Finance
Atrium Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network
Atrium Therapeutics, Inc. (RNA) - DirectorsTalk Interviews
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform? - Yahoo Finance
Atrium Therapeutics, Inc. Share Price Live Today – NASDAQ:RNA Stock Price, Chart, News, History - upstox.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: A Biotech Player with a Potential 89% Upside - DirectorsTalk Interviews
BRIEF-Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - Dailyhunt
A new Atrium hire gets options on 11,000 shares and 5,500 restricted units - Stock Titan
Atrium (RNA) Momentum: Records a 1.68% Decrease to $13.48; Technical View: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingBreakaway Gap - vinanet.vn
Atrium (RNA) Earnings Reading: Profit Per Share Clears Its Benchmark for the Current Session; Price Reaction: The Stock Gains 6.78% in Latest TradingProfitability Analysis - careplusvn.com
Atrium (RNA) Closing Snapshot: Closes 0.93% Lower at $12.84 in Latest Trading; Level Check: the Supplied Trading Band Runs From $12.20 to $13.48 in the Latest ReadingStop Loss Guidance - vinanet.vn
Atrium Therapeutics (RNA) Inches Higher: 0.93% Gain Reinforces Support ZoneDark Pool Sentiment - vinanet.vn
Atrium Therapeutics (RNA) Climbs 2.4% as Shares Hold Above Critical SupportCup and Handle - dars.gov.et
Atrium Therapeutics, Inc. (RNA) Stock Analysis: 94.70% Potential Upside Catches Investor Attention - DirectorsTalk Interviews
Atrium Therapeutics (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Investor SentimentDividend Earnings Report - vinanet.vn
Atrium Therapeutics (RNA) Jumps 4.14% to $12.84 as Buyers Defend Key SupportValue Area High - vinanet.vn
Atrium Therapeutics (RNA) Climbs 4.1% to $12.84 as Biotech Sentiment StrengthensLow Beta Factor - Vinanet
Atrium Therapeutics (RNA): RA Capital and affiliates report 0% beneficial ownership - Stock Titan
Aterian: Q2 Earnings Snapshot - AOL.com
Sessa Capital discloses 8.8% Atrium Therapeutics (RNA) ownership through managed funds - Stock Titan
T. Rowe Price Associates (RNA) discloses 8.6% Atrium Therapeutics ownership in 13G/A - Stock Titan
Atrium Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | RNA | US04965N1046 - marketscreener.com
Atrium Therapeutics Q2 Net Loss Widens to $21.6 Million on Higher Spending - Minichart
Atrium Therapeutics Earns $15M BMS Milestone Payment, Advances Gene Therapy Candidate - Minichart
FDA clears IND for Atrium Therapeutics' ATR 1072 trial - scanx.trade
Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Heart drug developer Atrium Therapeutics' Q2 loss widens as expenses rise - TradingView
Atrium Therapeutics Q2 Results: Sales beat 50%, EPS miss widens - scanx.trade
Atrium Therapeutics, Inc. Q2 2026: Revenue $3M, EPS $(1.18) — 10-Q Summary - TradingView
Atrium Therapeutics (RNA) grows collaboration revenue to $22.6M while scaling R&D spend - Stock Titan
Atrium Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Atrium Therapeutics Reports Second Quarter 2026 Financial Results - KITV
Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series B - Fierce Biotech
Atrium Therapeutics Earns $15M BMS Milestone - Contract Pharma
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb By Investing.com - Investing.com Nigeria
Atrium Therapeutics Earns Another $15 Million Milestone Payment From Bristol Myers Squibb - marketscreener.com
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb - Investing.com
Fate Therapeutics: Q2 Earnings Snapshot - AOL.com
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PR Newswire
3.06%
2.55%
자본화:
|
볼륨(24시간):